

CLINICAL IMAGE

Primary myelofibrosis evolving to an aplastic appearing marrow

Jordan K. Schaefer¹  | Sarah M. Choi²  | Gary D. Luker^{3,4,5} |
Thomas L. Chenevert³ | Brian D. Ross^{3,6} | Moshe Talpaz¹ 

¹Division of Hematology/
Oncology, Department of Internal
Medicine, University of Michigan, Ann
Arbor, MI, USA

²Department of Pathology, University of
Michigan, Ann Arbor, MI, USA

³Department of Radiology, Center for
Molecular Imaging, University of Michigan,
Ann Arbor, MI, USA

⁴Department of Biomedical
Engineering, University of Michigan, Ann
Arbor, MI, USA

⁵Department of Microbiology and
Immunology, University of Michigan, Ann
Arbor, MI, USA

⁶Department of Biological
Chemistry, University of Michigan, Ann
Arbor, MI, USA

Correspondence

Moshe Talpaz, University of Michigan
Health System, Comprehensive Cancer
Center, Ann Arbor, MI, USA.
Email: mtalpaz@med.umich.edu

Funding information

National Institutes of Health, Grant/Award
Number: R35 CA197701

Key Clinical Message

Our case highlights a series of bone marrow biopsies from a patient with primary myelofibrosis. Over time, this patient developed an unusual fatty appearance to his marrow, confirmed on multiple biopsies. This finding was supported by a quantitative fat MRI sequence that also shows a fatty appearance to the marrow.

KEYWORDS

aplasia, myelopoiesis, neoplasia, pathology, primary myelofibrosis

1 | CASE

A 54-year-old man was diagnosed with *MPL* mutated, primary myelofibrosis in 2004 with a hypercellular marrow, MF-2 fibrosis with megakaryocytic atypia, peripheral leukoerythroblastosis, splenomegaly, and an elevated lactate dehydrogenase. He was observed until 2010, when he was started on hydroxycarbamide for increasing symptoms. Prior to his 2011 enrollment in a clinical trial utilizing a novel JAK2 inhibitor, fedratinib, a bone marrow biopsy (Figure 1, Panel A; hematoxylin and eosin stain above, reticulin stain

below, 10×) showed progressive megakaryocytic atypia and MF-3 fibrosis. Nearly 1 year into the trial, a repeat bone marrow (Figure 1, Panel B; hematoxylin and eosin stain above, reticulin stain below, 20×) was hypocellular with MF-3 fibrosis only in the cellular areas. The patient was taken off trial in 2013 and started on ruxolitinib. Repeat bone marrow biopsies in 2016 (Figure 1, Panel C; hematoxylin and eosin stain above, reticulin stain below, 10×) show a marrow comprised entirely of adipose tissue with osteosclerosis. Quantitative fat magnetic resonance (MR) imaging, utilizing methods reported separately,¹ shows replacement of the




FIGURE 1 Histopathological findings from sequential bone marrow biopsies (panels A-D) of a patient with primary myelofibrosis that ultimately developed fatty replacement of his marrow. (H&E, top panels; Reticulin, bottom panels)




FIGURE 2 Quantitative fat MRI shows replacement of bone marrow with fat. (Top row) Representative transaxial image of the pelvis shows water-only (left) and fat-only (only) acquisitions from a quantitative fat imaging sequence. Yellow arrows show iliac crests. (Bottom row) Images display the percent fat in each voxel with a grayscale display (right) or pseudocolor display that depicts 100% fat and 0% fat as red and dark blue, respectively (left). Percent fat in bone marrow approximates values measured in subcutaneous fat (orange arrow)

marrow with fat. Representative transaxial MR images of the pelvis show water-only, and fat-only (Figure 2, top row) constituents. Arrows show the iliac crests. A representative pseudocolor display that depicts 100% fat as dark red and 0% fat as dark blue is shown (Figure 2, bottom row). The percent fat evident in the bone marrow imaging approximates that in the subcutaneous fat. After 3 bone marrow biopsies and the MR demonstrating this unusual transition of primary myelofibrosis to a fatty, aplastic appearing marrow, a repeat bone marrow in 2017 (Figure 1, Panel D; hematoxylin and eosin stain above, reticulin stain below, 20 \times) now showed a hypocellular marrow with histopathologic findings consistent with his marrow at the time of diagnosis. To our knowledge, this is the first case of a fibrotic marrow developing

such an aplastic appearance in a patient treated with a JAK2 inhibitor.

ACKNOWLEDGMENTS

This work was supported in part by NIH grant R35CA197701.

AUTHOR CONTRIBUTION

JKS and MT: compiled the clinical information and wrote the manuscript. SMC: provided the photomicrographs and descriptions of the bone marrow biopsies. GDL, TLC, and BDR: provided the MRI images and descriptions. GDL, TLC, BDR, MT: developed and wrote IRB amendments to

include advanced MRI protocols. All authors reviewed and approved the manuscript.

CONFLICT OF INTERESTS

Dr. Talpaz is on the advisory board for CTI Biopharma and Gilead. He has received travel support from Ariad. The remaining authors have no relevant conflicts of interest.

ORCID

Jordan K. Schaefer  <http://orcid.org/0000-0002-7166-386X>

Sarah M. Choi  <http://orcid.org/0000-0002-7028-7313>

Moshe Talpaz  <http://orcid.org/0000-0003-3361-3981>

REFERENCE

1. Luker GD, Nguyen HM, Hoff BA, et al. A pilot study of quantitative MRI parametric response mapping of bone marrow fat for treatment assessment in myelofibrosis. *Tomography*. 2016;2:67-78.

How to cite this article: Schaefer JK, Choi SM, Luker GD, Chenevert TL, Ross BD, Talpaz M. Primary myelofibrosis evolving to an aplastic appearing marrow. *Clin Case Rep*. 2018;6:1393–1395. <https://doi.org/10.1002/ccr3.1618>